Caribou Biosciences (CRBU) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Caribou Biosciences (NASDAQ: CRBU):

• 10/8/2026 – Caribou Biosciences was downgraded by HC Wainwright from “buy” to “neutral”.
• 10/7/2026 – Caribou Biosciences was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $1.00 price target on the stock.
• 10/7/2026 – Caribou Biosciences had its “market perform” rating reaffirmed by Leerink Partners. They now have a $1.00 price target on the stock, down from $4.00.
• 10/7/2026 – Caribou Biosciences was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $1.00 price target on the stock.
• 10/7/2026 – Caribou Biosciences was downgraded by Brookline Capital Markets from “buy” to “hold”.
• 9/19/2026 – Caribou Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/14/2026 – Caribou Biosciences had its price target lowered by Bank of America Corporation from $6.00 to $5.00. They now have a “buy” rating on the stock.

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.